BeStock  
Stocks › Biotechnology › NTLA

Intellia Therapeutics NTLA

US equityMarket cap rank #2862BiotechnologyGene Editing
$12.75 +$0.49 (+4.00%)
Pre-market · Oct 6, 4:10 am ET · After hours $12.75 0.00%
Open$12.35
Prev close$12.26
Day range$11.85 – $12.88
Volume4.97M
Market cap$1.79B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-3.8x
CheapRich

Above its usual level · 64th percentile, 5-year average -7.8x

P/E over five years

-51x-32x-14x5xOct '21Apr '24Oct '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$27.00
Price vs. fair value-52.8%Trading below the estimate
Star rating★★★★★
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PE -3.82 -4.07 -7.81 64% (pricier than usual) –

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★★★
Fair value estimate$27.00
Economic moatNone
UncertaintyVery High

Discussion

No comments yet — be the first to weigh in on NTLA.

Leave a comment

Scroll to Top